Aquestive Therapeutics Q2 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) reported Q2 revenue of $13.8M, up 38% year over year, and a net loss of $22.9M ($0.18/share). Excluding a $11.7M debt-extinguishment loss, net loss was $11.2M. The company discussed FDA resubmission review timing for Anaphylm, cash of $98.5M, and maintained 2026 guidance of $46M to $50M revenue.
How this was made
The 30-second read
Why it matters
Traders may reprice the probability-weighted timeline to Anaphylm approval based on management’s expectation of a focused resubmission package and the FDA’s discretion between Class 1 and Class 2 review, while also monitoring cash burn and financing flexibility.
Market read
Q2 earnings included revenue growth, maintained full-year guidance, and a refinancing that improves flexibility, alongside FDA resubmission review-time framing for Anaphylm.
What to watch
The $11.7M one-time debt-extinguishment loss and rising SG&A (legal, severance, personnel) may pressure sentiment even with improved adjusted EBITDA and a lower cost of capital.
Background
Aquestive’s Q2 call covered Anaphylm launch preparation, FDA resubmission review timing assumptions, refinancing, and early development updates for AQST-108.
Ticker impact
Aquestive reported Q2 revenue of $13.8M, maintained 2026 guidance, and discussed FDA resubmission review timing for Anaphylm.
Likely modest volatility around FDA review-time expectations and cash runway, with direction dependent on market read-through to Anaphylm resubmission speed.
The article provides fresh quarterly financials, guidance confirmation, and specific FDA review-classification discretion, but no approval decision or new FDA outcome.
Market effects
Highlights how FDA resubmission can be classified as a faster Class 1 versus slower Class 2 review, a key risk variable for specialty pharma with NDA resubmissions.
Mentions planned regulatory processes for Anaphylm in Canada, Europe, and the U.K., which can broaden approval optionality beyond the U.S.
If Anaphylm’s data package supports filings abroad, it can affect global commercialization expectations for branded epinephrine rescue products.
Counterpoint
The call emphasizes preparation and FDA review discretion, but does not provide a new FDA decision date or additional clinical efficacy data, limiting upside conviction.
Key entities
- companyAquestive Therapeutics
Specialty pharma developing PharmFilm drug delivery systems; discussed Q2 results, Anaphylm FDA resubmission expectations, and AQST-108 development.
- productAnaphylm
Potential epinephrine rescue product discussed in the context of FDA resubmission and possible launch preparation.
- productLibervant
Approved buccal diazepam product; referenced via partnership/regulatory planning and revenue mix.
- financing_partnerOaktree
Refinancing partner that established a new $150M debt facility to lower cost of capital and extend interest-only period.
- financing_partnerRTW
Management expects $75M in launch funding from RTW after FDA approval of Anaphylm, subject to conditions.
